Dr. Naparstek is a graduate of the Hadassah-Hebrew University Medical School in Jerusalem, Israel. He is Boards certified in Internal Medicine, Rheumatology and Clinical Immunology and Allergy. Dr. Naparstek has been a research fellow and a visiting Professor at the Weizmann Institute of Science, Rehovot, Tuft’s University, Boston, The National Institute of Health, Bethesda and Stanford University, Stanford.
Dr. Naparstek is currently a Professor of Medicine in the Hebrew University, Jerusalem and the Head of the Master in Health Administration program in the Israel Academic College, Ramat Gan and the Scientific Director of the Meuhedet Research Institute. He has served as the Chairman of Medicine in the Hadassah University Hospital, as the Director of the Hadassah Clinical Immunology and Rheumatology Center as well as the deputy director of Hadassah for Research and Academic affairs.
Dr. Naparstek is the incumbent of the Leifferman Chair in Rheumatology.
His main research interests are in the field of autoimmunity, SLE, autoimmune arthritis and type 1 diabetes. In recent years his research group focused on the identification of the target antigens in SLE and in autoimmune arthritis and diabetes and in the attempts to develop antigen-specific therapeutic modalities and novel drug delivery systems for to those diseases.
Dr. Naparstek served as the Chairman of the Boards of the Israeli T-Cell Vaccination Center, and the head and founder of the Israeli SLE Registry. He is currently the Head of the Israeli Cell therapy and Gene therapy Committees and a member in many other national and international committees including the NIH Global Leaders for Precision Medicine, and the International researchers in Advances in Targeted Therapy.
Dr. Naparstek is the founder and chief scientist of the Verto Medical and Protab Therapeutics biotechnological companies and a consultant and SAB member in other medical-biotechnology companies. He is the recipient of national and international awards, including the 2011 Elkeles Prize in Medicine and the author of more than 100 publications and chapters in books as well as many patents in the field of autoimmune inflammatory diseases.
